chairs

    Mar
    27
    Mon
    CURE at Saint Joseph University Featuring: Susan Baserga – Resilience and Ribosomes: Practicing Persistence in Life and in the Lab @ University of Saint Joseph - Crystal Room, Mercy Hall, First floor.
    Mar 27 @ 4:00 pm – 6:00 pm

    CURE is pleased to collaborate with the University of Saint Joseph and with one of CT’s very talented scientists to discuss the delivery of excellence in research, administration, teaching and family. Light refreshments and opportuntity for networking following Dr. Baserga’s seminar.

    Host:

    Susan Froshauer, Ph.D., President & CEO of CURE, President of CURE Innovations, LLC.

    Susan is an experienced scientist, mentor, entrepreneur and angel investor with skill at connecting academic expertise and technology with the commercial sector. Susan is involved with the Yale Entrepreneurial Institute, the CTNEXT funded group, SECT Tech, the Creative Arts Workshop and the Angel Investor Forum. Prior to joining CURE, Dr. Froshauer was Director of the Technology Exchange Portal at the University of Connecticut’s Office of Economic Development. In this role Susan assisted Connecticut-based entrepreneurs and organizations with initiatives that train students, create jobs and contribute to economic development. She connected ideas with business expertise, business plans with investors and industry with scholars. Her passion and commitment is helping bioscience entrepreneurs build successful companies.

    Speakers:

    Susan Baserga, MD, Ph.D., Professor of Molecular Biophysics and Biochemistry, of Genetics and Therapeutic Radiology, Yale University

    Susan Baserga received a B.S. in Biology from Yale College and an M.D. and Ph.D. (Human Genetics) from Yale in 1988.  She conducted post-doctoral training in the Department of Molecular Biophysics and Biochemistry at Yale with Joan Steitz.  Susan is currently an Associate Professor at Yale University with a primary appointment in Molecular Biophysics & Biochemistry and joint appointments in the Departments of Genetics and Therapeutic Radiology.  The focus of Susan’s research is on the function of ribonucleoproteins in pre-rRNA processing and pre-ribosome assembly.  Her research is principally funded by the National Institutes of Health and the National Science Foundation.

    Melissa Marcucci, Ph.D., Associate Professor and Chair, Department of Biology, USJ

    Serving as a tenured faculty member and Chair in the biology department at the University of Saint Joseph (USJ), Dr. Marcucci has provided students with a wide range of necessary tools to succeed in biology-based professions and STEM graduate programs.  She has shared her knowledge of biology in the classroom in a teaching and advisory capacity, as well as in the research laboratory.  Until becoming Chair, Dr. Marcucci maintained a research affiliation in the department of internal medicine at Yale University where she studied the molecular defects of insulin signaling in type 2 diabetes.  Dr. Marcucci also served as the Director of the CREC Summer Institutes for Science and Math for three summer, a collaboration with the Capitol Regions Education Council, to offer summer residence programs at USJ to select area high school students demonstrating academic excellence in STEM fields.  Currently, Dr. Marcucci currently serves as the Chair of the department of biology at USJ, a large complex department that is active in research and has a strong curriculum preparing students for professional careers in biomedical research, medicine, pharmaceutical sciences, and industry.  Aside from her passion for the biological sciences, Dr. Marcucci also advocates for leadership opportunities for women in science.

    Directions and Parking:

    Informational map showing the buildings and the exact location of talk on USJ campus: http://www.usj.edu/files/9514/7005/6952/campus_map.pdf

    Refer to above map for parking at USJ:  best locations for parking are the large lots adjacent to the Center for Applied Research and Education (CARE) Building (#18 on map), visitors spots behind Mercy Hall (#1), and the large lot behind the Pope Pius XII Library (#12) (note that the numbers correspond to locations on the map)

    Driving directions to USJ:  http://www.usj.edu/about-us/maps-directions/driving-direct/

    SPONSORS:

        

    Mar
    28
    Tue
    BioHaven Presents: Biohaven Pharmaceuticals – Targeting Orphan Neurologic Indications and Other Neurological Pathways @ Anylan Center at Yale
    Mar 28 @ 4:00 pm – 6:00 pm

    CURE is delighted to kick-off its spring series Yale-Biohaven series with a presentation by Vlad Coric about the start and growth of his company Biohaven Pharmaceuticals. We welcome to this event students, faculty, start-ups, investors, growing companies and individuals interested in learning about the CT bioscience community.

    Biohaven has licensed intellectual property from Yale U. Mass. General Hospital, Rutgers, Catalent, ALS Biopharma LLC and large pharmaceutical companies. The Company’s first drug candidate, BHV-0223, is a novel formulation of a glutamate-modulating agent, being developed under FDA 505(b)(2) guidelines for Amyotrophic Lateral Sclerosis (or Lou Gehrig’s disease). The FDA cleared the Company’s IND for the agent in August 2015, and Biohaven has completed a pharmacokinetic study in humans and is planning to launch a pivotal bioequivalence study presently. Biohaven’s second clinical compound, trigriluzole, is a New Molecular Entity for neurodegenerative diseases, neuropsychiatric disorders and potentially cancer indications. It is exciting that Biohaven completed an $80M financing in 4Q’16 to advance these programs. This positioned Biohaven among the top five series A private funding rounds of 2016, according to BioWorld Snapshots. In their business model, the Company plans to advance other approaches and is actively exploring licenses for additional compounds.

    We will hear more about this at the event.

    Host:

    Susan Froshauer, Ph.D., President & CEO of CURE, President of CURE Innovations, LLC

    Susan is an experienced scientist, mentor, entrepreneur and angel investor with skill at connecting academic expertise and technology with the commercial sector. Susan is involved with the Yale Entrepreneurial Institute, the CTNEXT funded group, SECT Tech, the Creative Arts Workshop and the Angel Investor Forum. Prior to joining CURE, Dr. Froshauer was Director of the Technology Exchange Portal at the University of Connecticut’s Office of Economic Development. In this role Susan assisted Connecticut-based entrepreneurs and organizations with initiatives that train students, create jobs and contribute to economic development. She connected ideas with business expertise, business plans with investors and industry with scholars. Her passion and commitment is helping bioscience entrepreneurs build successful companies.

    Speaker:

    Vlad Coric, M.D.
    Chief Executive Officer and Director, Biohaven Pharmaceuticals, Inc.

    Dr. Coric has served as the chief executive officer and director of Biohaven since October 2015. Biohaven is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders.  Dr. Coric has helped Biohaven raise over $100M since its inception, and investors include leading biotech funds such as Venrock, RA Capital Management, Vivo Capital, Aisling Capital, Rock Springs Capital, John W. Childs, Knoll Capital Management, Osage University Partners, Aperture Venture Partners, Connecticut Innovations, Greg Bailey and Litmore Capital.

    Dr. Coric has more than 15 years of drug discovery and clinical development experience at Yale School of Medicine and Bristol-Myers Squibb. Within the pharmaceutical industry, Dr. Coric has expertise working across therapeutic areas including neuroscience, virology, oncology and immuno-oncology. Most recently, Dr. Coric was the immuno-oncology indication lead for neuro-oncology and glioblastoma. He has been involved in multiple drug development programs including marketed drugs such as ABILIFY® (aripiprazole; partial dopamine agonist), OPDIVO® (nivolumab; anti-PD1), YERVOY® (Ipilimumab; anti-CTLA-4), DAKLINZA® (daclatasvir; NS5A inhibitor) and SUNVEPRA® (asunaprevir; NS3 inhibitor). He has conducted numerous clinical trials in various illnesses including obsessive compulsive disorder, generalized anxiety disorder, major depression, schizophrenia, schizoaffective disorder, Alzheimer’s disease, hepatocellular carcinoma, and glioblastoma. Dr. Coric was the first to report the therapeutic effects of the glutamate-modulating agent riluzole in neuropsychiatric disorders (Coric et al., 2003; 2005; Sanacora et al., 2004) and led the first clinical trial employing cerebrospinal fluid biomarkers to identity and enrich for patients with Prodromal Alzheimer’s Disease while at Bristol-Myers Squibb (Coric et al 2015). Additionally, Dr. Coric spearheaded the design of and led the first global registrational trial using checkpoint inhibitors in glioblastoma. Dr. Coric is an Associate Clinical Professor of Psychiatry at the Yale School of Medicine and has over 50 peer-reviewed publications. He previously served as Chief of the Yale Clinical Neuroscience Research Unit, and Director of the Yale Obsessive-Compulsive Disorder Research Clinic. He has served as President of the Connecticut Psychiatric Society (an 800 member district branch of the American Psychiatric Association). Dr. Coric completed residency training at the Yale Psychiatry Residency Training Program, where he also served as the Program-Wide Chief Resident for the Yale Department of Psychiatry, and Chief Resident on the PTSD firm at the West-Haven Connecticut Veterans Administration Hospital. Dr. Coric earned his medical degree at Wake Forest University School of Medicine in North Carolina.

    Sponsors:

     

    Apr
    20
    Thu
    Thirsty Thursdays at The Commons @ CURE Innovation Commons
    Apr 20 @ 4:30 pm

    Thirsty for networking, knowledge or a cold beverage? Join us at The Commons for a series of networking events with executives who have started businesses in CT.

    Join our MeetUp Group

    Follow us on Twitter @curecommons.

    thirsty-thursdays-frontR1

     

     

    Apr
    24
    Mon
    CT ENTREPRENEUR AWARDS @ Stony Creek Brewery in Branford
    Apr 24 @ 6:00 pm – 8:00 pm

    More details to come.

    Apr
    25
    Tue
    BioHaven Presents: Dr. John LaMattina – The Biopharmaceutical Industry’s Challenges in Drug Pricing
    Apr 25 @ 4:00 pm – 6:00 pm

    CURE is very pleased that Dr. LaMattina has agreed to return to our Biohaven series to discuss drug pricing transparency.   This discussion is suitable for the general public, legislators, students, faculty, and healthcare stakeholders.

    Host:

    Susan Froshauer, Ph.D., President & CEO of CURE, President of CURE Innovations, LLC

    Susan is an experienced scientist, mentor, entrepreneur and angel investor with skill at connecting academic expertise and technology with the commercial sector. Susan is involved with the Yale Entrepreneurial Institute, the CTNEXT funded group, SECT Tech, the Creative Arts Workshop and the Angel Investor Forum. Prior to joining CURE, Dr. Froshauer was Director of the Technology Exchange Portal at the University of Connecticut’s Office of Economic Development. In this role Susan assisted Connecticut-based entrepreneurs and organizations with initiatives that train students, create jobs and contribute to economic development. She connected ideas with business expertise, business plans with investors and industry with scholars. Her passion and commitment is helping bioscience entrepreneurs build successful companies.

     

    Speaker:

    Dr. John LaMattina is the former Senior Vice President of Pfizer Inc. and former President of Pfizer Global Research and Development. In that role, Dr. LaMattina oversaw the drug discovery and development efforts of over 12,000 colleagues in the United States, Europe and Asia. During his tenure as head of global R&D, Pfizer produced new treatments for cancer, smoking cessation, rheumatoid arthritis and AIDS.

    Dr. LaMattina is the author of numerous scientific publications and holds a number of U.S. patents. In addition, he is the author of “Drug Truths: Dispelling the Myths About Phama R&D” and “Devalued and Distrusted – Can the Pharmaceutical Industry Restore Its Broken Image?” He is also a contributor to Forbes.com.

    He is currently a Senior Partner at PureTech Health and serves on the Board of Directors of Ligand Pharmaceuticals, Zafgen, Gelesis and Vedanta Biosciences.

     

    Thank You to Our Sponsors:

     

    May
    11
    Thu
    The CT Women’s Hall of Fame and CURE Innovation Commons STEMFems Event @ CURE Innovation Commons
    May 11 all-day

    More details to follow.

    May
    18
    Thu
    Thirsty Thursdays at The Commons @ CURE Innovation Commons
    May 18 @ 4:30 pm

    Thirsty for networking, knowledge or a cold beverage? Join us at The Commons for a series of networking events with executives who have started businesses in CT.

    Join our MeetUp Group

    Follow us on Twitter @curecommons.

    thirsty-thursdays-frontR1

     

     

    Jun
    13
    Tue
    CURE Annual Meeting & BioScience & Technology Picnic @ CURE Innovation Commons
    Jun 13 @ 4:00 pm – 7:00 pm

    More details to follow.